Bile and fat excretion are biomarkers of clinically significant diarrhoea and constipation in irritable bowel syndrome

2019 ◽  
Vol 49 (6) ◽  
pp. 744-758 ◽  
Author(s):  
Priya Vijayvargiya ◽  
Michael Camilleri ◽  
Duane Burton ◽  
Irene Busciglio ◽  
Alan Lueke ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Clinically Significant ◽  
Irritable Bowel ◽  
Fat Excretion

Fecal fat excretion in irritable bowel syndrome

2012 ◽  
Vol 47 (8-9) ◽  
pp. 1120-1121 ◽  
Author(s):  
Arnold Berstad ◽  
Mette Helvik Morken ◽  
Gülen Arslan Lied ◽  
Ragna Lind ◽  
Aud-Sissel Hjartholm ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Fecal Fat ◽  
Irritable Bowel ◽  
Fat Excretion

scholarly journals Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity

2017 ◽  
Vol 62 (9) ◽  
pp. 2455-2463 ◽  
Author(s):  
M. Pimentel ◽  
B. D. Cash ◽  
A. Lembo ◽  
R. A. Wolf ◽  
R. J. Israel ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Antibiotic Sensitivity ◽  
Clinically Significant ◽  
Irritable Bowel

scholarly journals Are Faecal Microbiota Analyses on Species-Level Suitable Clinical Biomarkers? A Pilot Study in Subjects with Morbid Obesity

2021 ◽  
Vol 9 (3) ◽  
pp. 664
Author(s):  
Per G. Farup ◽  
Maria G. Maseng
Keyword(s):  
Morbid Obesity ◽  
Irritable Bowel Syndrome ◽  
Multiple Testing ◽  
Bacterial Species ◽  
Alpha Diversity ◽  
Faecal Microbiota ◽  
Clinical Biomarkers ◽  
Clinically Significant ◽  
Irritable Bowel ◽  
Microbiome Profiling

Background: An abnormal faecal microbiota could be a causal factor for disease. This study evaluated a new method for faecal microbiota analysis in subjects with obesity and irritable bowel syndrome. Methods: The study had a matched case-control design. Forty-six subjects with morbid obesity (defined as BMI > 40 or >35 kg/m2 with obesity-related complications) of whom 23 had irritable bowel syndrome (IBS), were compared with 46 healthy volunteers. The faecal microbiota was analysed with Precision Microbiome Profiling (PMP™) which quantified 104 bacteria species. The primary aim was comparisons between the cases and controls. Results: Two men and 44 women with a mean age of 43.6 years were included in each of the groups; BMI in the groups was (mean and SD) 41.9 (3.5) and 22.5 (1.5) kg/m2, respectively. Seventeen bacterial species showed statistically significant differences between the groups after adjusting for multiple testing. In a post hoc analysis, the sensitivity and specificity were 78%. Alpha diversity was lower in the group with obesity. In subjects with morbid obesity, no clinically significant differences were seen between subjects with and without IBS or from before to six months after bariatric surgery. Conclusions: The results encourage further evaluation of the new microbiome profiling tool.

Acupuncture for Irritable Bowel Syndrome – An Exploratory Randomised Controlled Trial

2008 ◽  
Vol 26 (1) ◽  
pp. 8-16 ◽  
Author(s):  
Julie A Reynolds ◽  
J Martin Bland ◽  
Hugh MacPherson
Keyword(s):  
Irritable Bowel Syndrome ◽  
Randomised Controlled Trial ◽  
Sample Size ◽  
Primary Outcome ◽  
Controlled Trial ◽  
Full Scale ◽  
Clinically Significant ◽  
Irritable Bowel ◽  
Randomised Controlled ◽  
Gp Care

Background The evidence on the effectiveness of acupuncture for irritable bowel syndrome (IBS) is inconclusive. However, many patients with IBS are self referring for acupuncture, therefore it is of interest to know whether acupuncture is effective or not. The aim of this study was to establish variability in the primary outcome measure to enable a sample size to be calculated for a full scale trial, and to explore feasibility and design criteria. Methods A pragmatic randomised controlled trial compared 10 sessions of acupuncture plus usual GP care with usual GP care alone. Thirty patients were recruited from four GP databases in Birmingham, UK, and randomised one-to-two to acupuncture or usual care alone. The primary outcome was the IBS Symptom Severity Score (SSS) at three months (maximum score 500). Analysis was by intention-to-treat, and multiple imputation was used for missing data. Results From the databases, 189 patients with IBS were identified, of whom 30 were eligible and consented to randomisation. At three months, a statistically and clinically significant difference between groups of 138 points (SD 90) in favour of acupuncture was observed on the IBS SSS (95% CI: 66 to 210; P=0.001) using multiple imputation. For a full scale trial, we estimate that a sample size of 108 patients per arm is required, based on a minimum clinically significant change of 50 points, drawn from a primary care population of 140 000. Conclusions We established the feasibility of a full scale trial, successfully recruiting patients and calculating the sample size required. The results of our pilot analysis suggest that more definitive research into acupuncture for IBS is merited. A pragmatic trial design will not be able to distinguish between acupuncture specific effects and placebo effects; however, it is the design of choice to determine cost effectiveness.

Motor and sensory function of the rectum in different types of irritable bowel syndrome

2001 ◽  
Vol 120 (5) ◽  
pp. A399-A399
Author(s):  
J STEENS ◽  
P SCHAAR ◽  
C LAMERS ◽  
A MASCLEE
Keyword(s):  
Irritable Bowel Syndrome ◽  
Sensory Function ◽  
Different Types ◽  
Irritable Bowel

Rome I versus Rome II; Overlap in patients enrolled in tegaserod phase III clinical trials for irritable bowel syndrome (IBS)

2001 ◽  
Vol 120 (5) ◽  
pp. A284-A284
Author(s):  
B NAULT ◽  
S SUE ◽  
J HEGGLAND ◽  
S GOHARI ◽  
G LIGOZIO ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Irritable Bowel Syndrome ◽  
Phase Iii ◽  
Phase Iii Clinical Trials ◽  
Irritable Bowel ◽  
Rome I
Sign in / Sign up

Export Citation Format

Share Document